BioXcel Therapeutics (BTAI) Debt Ratio (2018 - 2026)

BioXcel Therapeutics' Debt Ratio history runs 9 years deep, the most recent figure standing at 2.95 for Q1 2026.

• On a quarterly basis, Debt Ratio rose 7.72% year-over-year to 2.95 in Q1 2026; TTM through Mar 2026 was 2.95, a 7.72% increase from a year earlier, with the FY2025 full-year figure at 2.44, down 8.74% from the prior year.
• Debt Ratio improved to 2.95 in Q1 2026 per BTAI's latest filing, from 2.44 in the prior quarter.
• Across five years, Debt Ratio topped out at 4.21 in Q2 2025 and bottomed at 0.0 in Q1 2022.
• The 5-year median for Debt Ratio is 1.36 (2023), against an average of 1.59.
• Across the five-year window, Debt Ratio jumped 199612.67% in 2023 and dropped 8.74% in 2025, its largest moves.
• Year by year, Debt Ratio stood at 0.45 in 2022, then soared by 200.59% to 1.36 in 2023, then surged by 95.89% to 2.67 in 2024, then decreased by 8.74% to 2.44 in 2025, then advanced by 20.8% to 2.95 in 2026.
• Per Business Quant, the three latest BTAI Debt Ratio figures stand at 2.95 (Q1 2026), 2.44 (Q4 2025), and 2.44 (Q3 2025).